ATE515699T1 - Verwendung von adiponectin als marker in der vorhersage post-operativer infektion - Google Patents

Verwendung von adiponectin als marker in der vorhersage post-operativer infektion

Info

Publication number
ATE515699T1
ATE515699T1 AT05727482T AT05727482T ATE515699T1 AT E515699 T1 ATE515699 T1 AT E515699T1 AT 05727482 T AT05727482 T AT 05727482T AT 05727482 T AT05727482 T AT 05727482T AT E515699 T1 ATE515699 T1 AT E515699T1
Authority
AT
Austria
Prior art keywords
adiponectin
marker
prediction
post
operative infection
Prior art date
Application number
AT05727482T
Other languages
English (en)
Inventor
Kazuhisa Maeda
Hiroshi Yamamoto
Original Assignee
Kazuhisa Maeda
Hiroshi Yamamoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kazuhisa Maeda, Hiroshi Yamamoto filed Critical Kazuhisa Maeda
Priority claimed from PCT/JP2005/006395 external-priority patent/WO2005094188A1/ja
Application granted granted Critical
Publication of ATE515699T1 publication Critical patent/ATE515699T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
AT05727482T 2004-03-31 2005-03-31 Verwendung von adiponectin als marker in der vorhersage post-operativer infektion ATE515699T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004134824 2004-03-31
JP2004134823 2004-03-31
PCT/JP2005/006395 WO2005094188A1 (ja) 2004-03-31 2005-03-31 侵襲管理方法及びアディポネクチンの利用

Publications (1)

Publication Number Publication Date
ATE515699T1 true ATE515699T1 (de) 2011-07-15

Family

ID=35064193

Family Applications (2)

Application Number Title Priority Date Filing Date
AT10185392T ATE544467T1 (de) 2004-03-31 2005-03-31 Adiponectin als endotoxin neutralisierendes agenz
AT05727482T ATE515699T1 (de) 2004-03-31 2005-03-31 Verwendung von adiponectin als marker in der vorhersage post-operativer infektion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT10185392T ATE544467T1 (de) 2004-03-31 2005-03-31 Adiponectin als endotoxin neutralisierendes agenz

Country Status (7)

Country Link
US (2) US20080139468A1 (de)
EP (2) EP2279745B1 (de)
JP (2) JP4771940B2 (de)
KR (2) KR20110128941A (de)
CN (1) CN1969187A (de)
AT (2) ATE544467T1 (de)
ES (1) ES2365923T3 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2365923T3 (es) 2004-03-31 2011-10-13 Kazuhisa Maeda Uso de adiponectina como marcador en la predicción de infección postoperatoria.
JP5432567B2 (ja) 2008-04-16 2014-03-05 花王株式会社 アディポネクチン分泌調節剤の評価又は選択方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4237502A1 (de) * 1992-11-06 1994-05-11 Biometec Ges Fuer Bio Medizini Arzneimittel enthaltend Antiidiotyp-Antikörper gegen Anti-CD14-Antikörper
JP3018186B1 (ja) 1999-03-09 2000-03-13 大阪大学長 抗炎症剤、単球系細胞の増殖抑制剤
ATE405655T1 (de) * 2000-01-14 2008-09-15 Serono Genetics Inst Sa Obg3 globularekopf und seine verwendungen zur reduzierung des körpersgewichtes
DK1426764T3 (da) 2001-08-17 2011-06-27 Fujirebio Kk Fremgangsmåde til diagnosticering eller monitorering af fejl i sukkermetabolisme
EP1458758A2 (de) * 2001-12-21 2004-09-22 Maxygen Aps Adiponectin-fragmente und -konjugate
CA2473781A1 (en) * 2002-01-18 2003-07-31 Protemix Corporation Limited Glycoisoforms of adiponectin and uses thereof
WO2004022596A1 (en) * 2002-09-05 2004-03-18 Komed Co., Ltd. Monoclonal antibody against adiponectin, preparation method and use thereof
ES2365923T3 (es) 2004-03-31 2011-10-13 Kazuhisa Maeda Uso de adiponectina como marcador en la predicción de infección postoperatoria.

Also Published As

Publication number Publication date
EP2279745B1 (de) 2012-02-08
EP2279745A3 (de) 2011-02-16
KR20070026485A (ko) 2007-03-08
EP1744160B1 (de) 2011-07-06
US20130302833A1 (en) 2013-11-14
US20080139468A1 (en) 2008-06-12
KR20110128941A (ko) 2011-11-30
EP2279745A2 (de) 2011-02-02
JP4771940B2 (ja) 2011-09-14
WO2005094188A2 (ja) 2005-10-13
EP1744160A2 (de) 2007-01-17
CN1969187A (zh) 2007-05-23
US9341634B2 (en) 2016-05-17
WO2005094188A3 (ja) 2005-12-08
JPWO2005094188A1 (ja) 2008-02-14
JP2011121959A (ja) 2011-06-23
ATE544467T1 (de) 2012-02-15
ES2365923T3 (es) 2011-10-13
KR101223355B1 (ko) 2013-01-16
EP1744160A4 (de) 2008-05-21

Similar Documents

Publication Publication Date Title
DE602005022859D1 (de) Heteroarylbenzamidderivate zur verwendung als glk-aktivatoren bei der behandlung von diabetes
DE602005009318D1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
FI20031699L (fi) Järjestely, menetelmä ja tietokoneohjelma ihmisen fyysisen aktiivisuustason määrittämiseksi
DE602006003787D1 (de) Bestimmung der tatsächlichen Zeit, die ein Prozessor bei der Ausführung eines Codeteiles aufwendet
DK1718756T3 (da) Botulinumtoksinscreeningassays
ATE529042T1 (de) Verfahren zur quantifizierung des herztodrisikos unter verwendung von übungsinduzierten herzfrequenzvariabilitätsmetriken
TW200722753A (en) Meter having multi-level user interface
EP1809173A4 (de) Langzeitüberwachung zum nachweis von vorhofflimmern
ATE443703T1 (de) Prolinderivate als ns3-serine protease hemmer, zur verwendung bei der bekämpfung von hepatitis c virusinfektion
ATE546044T1 (de) Verwendung von alkylcarbonsäureamiden als penetrationsförderer
ATE375518T1 (de) Diagnoseverfahren für erkrankungen unter verwendung von copeptin
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
DE602005013923D1 (de) Derivate von piperidinylalkylcarbamaten, herstellungsverfahren davon und verwendung derselben als faah-enzym-inhibitoren
DE602005010821D1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
ATE445402T1 (de) Neue verwendung von pde5-hemmern
ATE486878T1 (de) Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin
ATE515699T1 (de) Verwendung von adiponectin als marker in der vorhersage post-operativer infektion
DE602005008325D1 (de) Quantifizierung von Enzymaktivität mittels planarer Wellenleiter
DK1790720T3 (da) Polypeptid med aktivitet af umættende omega3-fedtsyre, polynukleotid der koder for polypeptidet og anvendelse deraf
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
DE602005007817D1 (de) Analyse-Verfahren unter Verwendung von abgeschwächter Totalreflektion
DE602007008365D1 (de) Verfahren zur steigerung der lymphatischen funktion
NZ551782A (en) Agents and methods for diagnosing stress
DE602007004570D1 (de) Verwendung von Nogo-C bei der Beurteilung von Herzversagen
DE602004001509D1 (de) Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties